← Back to homepage
AstraZeneca sees stock market value slump by more than £20bn after drug setback
Sources
2
Coverage
Limited spectrum
Sentiment
-0.65
◀ Left 100%Centre 0%Right 0% ▶
How we rate bias →auto_awesome
NEWSDECK ANALYSIS
The coverage of AstraZeneca's stock market value slump by the Independent Business and the Evening Standard is broadly similar, with both reporting the company's £20bn loss after the Wainua drug failed to meet its goal. Both sources frame the story in a neutral tone, focusing on the facts of the drug's failure and its impact on AstraZeneca's stock market value. The language and emphasis used by the two outlets are nearly identical, indicating a consensus in their reporting of the event. The tone of the coverage is factual and objective, with no notable differences between the two sources.
This story is currently only covered by 2 sources from a limited part of the political spectrum. NewsDeck will update this page automatically if other outlets pick up the story.
NewsDeck Poll
Do you think this story is being covered fairly across the political spectrum?
Loading…
Left
(2)
Independent Business
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
9 Jul, 10:30
Evening Standard
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
9 Jul, 10:30
Centre
(0)
No coverage from this perspective yet
Right
(0)
No coverage from this perspective yet